Careful monitoring is essential due to gastrointestinal, dermatological, and cardiovascular risks, especially in vulnerable populations.

Vigilance for Adverse Reactions and Special Populations

Exelon can cause significant gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, anorexia, and weight loss, which may necessitate dose interruption or reduction. Patients with a history of hypersensitivity to rivastigmine or carbamate derivatives, or those with prior severe skin reactions to the patch, should not receive Exelon. Caution is advised in patients with asthma, obstructive pulmonary disease, cardiac conduction disorders, or those at risk for peptic ulcers. Dose adjustments are required for renal or hepatic impairment and low body weight. If therapy is interrupted for more than three days, retitration is mandatory to minimize severe adverse effects.